TrialDiabetes care2013
Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).
Julio Rosenstock et al.PubMed ↗Full text ↗Publisher ↗
The primary results report of NCT00707031. Its numbers are set against the trial’s posted results below.
No numbers read from the abstract.
Against the trial’s posted results
- Same as the trial’s posted resultThis paper difference 0.17 (0.03–0.30)Posted, primary outcome difference 0.17 (0.03–0.30)Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24
107 papers cite itlatest 60 shown
this paperpooled ittrialcites it